Business
Aussie biotech Starpharma signs deal to sell COVID nose spray in Britain – Sydney Morning Herald
The Melbourne-based firm’s market value is approaching the billion-dollar mark amid rising investor interest in its COVID-preventative treatment.
Australian biotech Starpharma is taking its COVID-fighting antiviral nasal spray to the world, signing a deal with UK chemist chain LloydsPharmacy to sell the product in Britain as the country emerges from lockdown.
The Melbourne-based company announced a deal on Thursday morning that will see its Viraleze virus-fighting product sold online in the UK starting next week. It will also be stocked in Lloyds 1400-strong pharmacy network.
Chief executive Jackie Fairley declined to comment on the value…
-
Noosa News8 hours agoLight plane crashes in Norwell, Gold Coast
-
Noosa News24 hours agoGreen spine to open in early 2026, stations to sit empty after completion next year
-
Business12 hours agoBerkshire Hathaway is a Scrooge stock. Will it have a change of heart and start paying dividends in 2026?
-
Business10 hours agoThese 3 ASX ETFs are all a beginner needs